SLGC
Somalogic Inc
19.10$
-0.4%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +14.6% | -28.6% | +262.1% | -1.7% | +1.0% | -3.8% | +0.3% | -5.9% | -5.1% | -4.6% | -3.5% | |
| – | -99.2% | +10,213.4% | +286.8% | -2.2% | -0.3% | -4.5% | -5.7% | -6.4% | -6.0% | -5.6% | -4.3% | |
| – | -99.0% | +2,860.8% | +894.3% | -6.2% | -0.3% | -4.5% | -9.0% | +10.9% | +4.0% | -19.1% | -13.8% | |
| – | +35.5% | -43.0% | +327.2% | -2.7% | -1.5% | -4.4% | -8.5% | -4.7% | -7.2% | -5.3% | -4.3% | |
| – | -14.6% | -8.9% | +8.3% | +16.2% | +28.3% | -37.5% | +83.1% | -32.1% | +50.4% | -15.0% | -4.7% | |
| – | +13.1% | -3.5% | +38.9% | +5.3% | +27.0% | +45.9% | -10.9% | -24.9% | +8.3% | +0.5% | -8.2% | |
| – | – | +26.0% | +47.4% | +47.3% | +24.2% | +33.6% | +25.6% | -1.7% | -64.3% | +47.4% | – | |
| – | – | – | – | – | – | – | – | -0.6% | +0.0% | +0.0% | +0.0% | |
| – | – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -7.4% | +334.1% | -59.1% | +1.6% | +1.9% | -17.7% | +8.5% | -0.9% | -6.9% | -10.6% | -3.2% | |
| – | -98.3% | +6,924.8% | +3.2% | +33.8% | -5.6% | +26.3% | +22.2% | +1.5% | -10.3% | -19.0% | -11.8% | |
| – | – | – | – | – | – | – | – | +1,721.3% | – | – | -0.9% | |
| – | +35.0% | -7.4% | +28.4% | +33.1% | +20.3% | +5.1% | +6.4% | -17.3% | +35.0% | -42.3% | -12.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -97.3% | -665.1% | – | -2.2% | +0.9% | -1.6% | -0.7% | -6.7% | -4.8% | -3.8% | -3.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -36.6% | +19.4% | +32.2% | +0.4% | +0.6% | +0.7% | +1.0% | +0.1% | +0.1% | +0.2% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.